Stiripentol Treatment Not Cost-Effective for Dravet Syndrome Patients in Canada, Study Says
Stiripentol is not a cost-effective treatment for Canadian Dravet syndrome patients, and decision-makers should consider funding it, according to a recent cost analysis. The study, “Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis,” was published in PharmacoEconomics. Combination therapy, or the use…